Antitumor activity of oxali-titanocene Y in xenografted CAKI-1 tumors in mice

Letters in Drug Design and Discovery

Volumn 5, Issue 8, 2008, Pages 489-493

  Fichtner, Iduna ^a   Behrens, Diana ^b   Claffey, James ^c   Gleeson, Brendan ^c   Hogan, Megan ^c   Wallis, Denise ^c   Weber, Holger ^d   Tacke, Matthias ^c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b Experimental Pharmacology and Oncology EPO GmbH   (Germany)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d PROQINASE GMBH   (Germany)

Author keywords

Anti angiogenesis; Anti cancer drug; CAKI 1; Cytotoxicity; HUVEC; Renal cell cancer; Titanocene; Xenograft

Indexed keywords

CD31 ANTIGEN; KI 67 ANTIGEN; OXALI TITANOCENE Y; OXALIC ACID; TITANOCENE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; UMBILICAL VEIN; VASCULARIZATION;

EID: 58049197862     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018008786898545     Document Type: Article

References (21)

1. Surveillance Epidemiology and End Results. National Cancer Institute; 2007. www.seer.cancer.gov.
2. Schrader, A.J.; Hofmann, R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-Cancer Drugs, 2008, 19, 235-245.
3. Lummen, G.; Sperling, H.; Luboldt, H.; Otto, T.; Rubben, H. Phase II trial of titanocene dichloride in advanced renal-cell carcinoma. Cancer Chemother. Pharmacol., 1998, 42, 415-417.
4. Kröger, N.; Kleeberg, U.R.; Mross, K.B.; Edler, L.; Saß, G.; Hossfeld, D.K. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Onkologie, 2000, 23, 60-62.
5. Allen, O.R.; Croll, L.; Gott, A.L.; Knox, R.J.; McGowan, P.C. Functionalized cyclopentadienyl titanium organometallic compounds as new antitumor drugs. Organometallics, 2004, 23, 288-292.
6. Strohfeldt, K.; Tacke, M. Bioorganometallic Fulvene-Derived Titanocene Anticancer Drugs. Chem. Soc. Rev., 2008, 37, 1174-1187.
7. Sweeney, N.J.; Mendoza, O.; Müller-Bunz, H.; Pampillón, C.; Rehmann, F.J.K.; Strohfeldt, K.; Tacke, M. Novel Benzyl Substituted Titanocene Anti-Cancer Drugs. J. Organomet. Chem., 2005, 690, 4537-4544.
8. Kelter, G.; Sweeney, N.; Strohfeldt, K.; Fiebig, H.H.; Tacke, M. In Vitro Anti-Tumor Activity of Bridged and Unbridged Benzyl-Substituted Titanocenes. Anti-Cancer Drugs, 2005, 16, 1091-1098.
9. Oberschmidt, O.; Hanauske, A.R.; Rehmann, F.J.K.; Strohfeldt, K.; Sweeney, N.; Tacke, M. Activity of [1,2-di(cyclopentadienyl)-1,2-di( p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride against Tumor Colony Forming Units. Anti-Cancer Drugs, 2005, 16, 1071-1073.
10. Oberschmidt, O.; Hanauske, A.R.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Activity of Titanocene Y against Tumor Colony Forming Units. Anti-Cancer Drugs, 2007, 18, 317-321.
11. O'Connor, K.; Gill, C.; Tacke, M.; Rehmann, F.J.K.; Strohfeldt, K.; Sweeney, N.; Fitzpatrick, J.M.; Watson, R.W.G. Novel Titanocene Anti-Cancer Drugs and their Effect on Apoptosis and the Apoptotic Pathway in Prostate Cancer Cells. Apoptosis, 2006, 11, 1205-1214.
12. Valadares, M.C.; Ramos, A.L.; Rehmann, F.J.K.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M.; Queiroz, M.L.S. Antitumor activity of [1,2-di(cyclopentadienyl)- 1,2-di(p-N,N-dimethylaminophenyl)-ethanediyl] titanium dichloride in xenografted Ehrlich's ascites tumor. Eur. J. Pharmacology, 2006, 534, 264-270.
13. Weber, H.; Claffey, J.; Hogan, M.; Pampillón, C.; Tacke, M. Analyses of Titanocenes in the Spheroid-based Cellular Angiogenesis Assay. Toxicol In Vitro, 2008, 22, 531-534.
14. Fichtner, I.; Bannon, J.; O'Neill, A.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Watson, R.W.G.; Tacke, M.; Mc Gee, M.M. Substituted Titanocenes Induce Caspase-dependent Apoptosis in Human Epidermoid Carcinoma Cells In Vitro and Exhibit Anti-tumor Activity In Vivo. Brit. J. Cancer, 2007, 97, 1234-1241.
15. Dowling, C.M.; Claffey, J.; Cuffe, S.; Fichtner, I.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Watson, R.W.G.; Tacke, M. Antitumor Activity of Titanocene Y in Xenografted PC3 Tumors in Mice. Lett. Drug Des. Discov., 2008, 5, 141-144.
16. Fichtner, I.; Pampillón, C.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Antitumor Activity of Titanocene Y in Xenografted Caki-1 Tumors in Mice. Anti-Cancer Drugs, 2006, 17, 333-336.
17. Beckhove, P.; Oberschmidt, O.; Hanauske, A.R.; Pampillón, C.; Schirrmacher, V.; Sweeney, N.J.; Strohfeldt, K.; Tacke, M. Antitumor Activity of Titanocene Y in Freshly Explanted Human Breast Tumors and in Xenografted MCF-7 Tumors in Mice. Anti-Cancer Drugs, 2007, 18, 311-315.
18. Claffey, J.; Hogan, M.; Müller-Bunz, H.; Pampillón, C.; Tacke, M. Oxali-Titanocene Y: A Potent Anticancer Drug. ChemMedChem, 2008, 3, 729-731.
19. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 1983, 65, 55-63.
20. Korff, T.; Augustin, H.G. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J. Cell. Biol., 1998, 143, 1341-1352.
21. Korff, T.; Augustin, H.G. Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. J. Cell. Sci., 1999, 112, 3249-3258.